CAR T-cell therapy now available at Princess Alexandra Hospital, Brisbane published June 3, 2025 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvin Read more
Tracking Long-term Effects of Cancer Treatment published April 28, 2025 Roughly 800 people are diagnosed with Hodgkin Lymphoma each year in Australia, and both adults and children ca Read more
CLL/SLL, MCL, MZL, WM – BRUKINSA® (Zanubrutinib) updates published April 7, 2025 The TGA has approved zanubrutinib for more people with lymphoma, and some of these are now PBS listed. Read more
CAR T-cell Therapy – Now available in 2nd line treatment published April 2, 2025 CAR T-cell therapy is an advanced treatment that helps your immune system fight the lymphoma. It involves coll Read more
Epcoritamab – New Treatment for DLBCL published April 2, 2025 Epcoritamab, (brand name EPKINLY®) is a new bispecific antibody treatment. It is now provisionally approved i Read more
Great news for patients with Mycosis Fungoides published January 23, 2025 LEDAGA® now PBS listed for patients with limited stage Mycosis Fungoides T-cell lymphoma. Read more
CAR T-cell Therapy now available in North Queensland published July 12, 2024 Gilead welcomes the opening of Australia’s first regional CAR T-cell treatment centre at Townsville Hospital Read more
Your Life Matters published November 6, 2023 Are you living (or caring for someone) with Chronic Lymphocytic Leukaemia or Small Lymphocytic Leukaemia? A g Read more
New CAR T Cell Therapy option now available in Australia for some patients with Lymphoma published August 5, 2021 Eligible patients can now access Yescarta through Royal Brisbane and Women’s Hospital, Brisbane and the Pete Read more
MabThera (rituximab) Update published March 30, 2021 IMPORTANT Information for all Lymphoma/ CLL Australian patients receiving MabThera® (rituximab) From Read more
Australian lymphoma patients will now have access to a new frontline therapy for CLL* published November 30, 2020 The combination of VENCLEXTA plus obinutuzumab will be available as a fixed duration therapy for previously un Read more
